PDL BioPharma, Inc. (Nasdaq: PDLI) announced that Roche has discontinued its involvement in the development of daclizumab in asthma, which ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE